DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

BETERNet Notch Signaling and Novel Biomarkers for Barretts Esophagus

Completed

Conditions: Barrett's Esophagus

First Posted Date: 2011-12-05

Last Posted Date: 2019-12-05

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 60

Registration Number: NCT01484925

Locations: 🇺🇸
Abramson Cancer Center, Philadelphia, Pennsylvania, United States

Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

Phase 1

Completed

Conditions: Adenocarcinoma Pancreas

First Posted Date: 2011-10-21

Last Posted Date: 2018-08-27

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 10

Registration Number: NCT01456585

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Experience of Non-Melanoma Skin Cancer (NMSC) Mohs Surgery Project

Completed

Conditions: Non-Melanoma Skin Cancer

First Posted Date: 2011-10-17

Last Posted Date: 2015-03-19

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 16

Registration Number: NCT01452984

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Proton Radiation for Chordomas and Chondrosarcomas

Not Applicable

Active, not recruiting

Conditions: Chondrosarcomas
Chordomas

Interventions: Radiation: Proton Therapy

First Posted Date: 2011-10-10

Last Posted Date: 2024-06-26

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 50

Registration Number: NCT01449149

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Proton Radiotherapy for Upper Gastrointestinal Malignancies

Not Applicable

Completed

Conditions: Gastrointestinal Cancer

Interventions: Radiation: Proton therapy

First Posted Date: 2011-10-10

Last Posted Date: 2020-04-15

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 22

Registration Number: NCT01449864

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

DCE-MRI PET Bevacizumab Study in Rectal Cancer

Phase 2

Withdrawn

Conditions: Rectal Cancer Patients

First Posted Date: 2011-08-31

Last Posted Date: 2018-08-21

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT01426074

Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine

Early Phase 1

Completed

Conditions: Myeloma

Interventions: Drug: Rapamycin
Drug: Hydroxychloroquine

First Posted Date: 2011-07-18

Last Posted Date: 2013-02-26

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 6

Registration Number: NCT01396200

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

DIBH Proton Planning

Completed

Conditions: Lymphomatous Malignancies
Lung Cancer
Breast Cancer
Gastrointestinal

First Posted Date: 2011-07-01

Last Posted Date: 2020-03-10

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 40

Registration Number: NCT01386697

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pelvic Floor Disorders in Survivors of Gynecologic Malignancies

Completed

Conditions: Uterine Cancer
Fallopian Tube Cancer
Ovarian Cancer
Cervical Cancer
Vulvar Cancer
Peritoneal Cancer

Interventions: Other: Survey

First Posted Date: 2011-06-09

Last Posted Date: 2020-04-29

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 225

Registration Number: NCT01370122

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Cardiovascular Effects of Sunitinib Therapy (CREST)

Completed

Conditions: Renal Cell Carcinoma 4

First Posted Date: 2011-06-09

Last Posted Date: 2018-10-02

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 98

Registration Number: NCT01370109

Locations: 🇺🇸
Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy